Evaluating the effects of the novel GLP1 analogue, Liraglutide, in patients with Alzheimer's Disease (ELAD study): a randomised, double-blind, placebo-controlled trial
Latest Information Update: 31 Jul 2024
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ELAD
- 30 Jul 2024 Primary endpoint(The change in cerebral glucose metabolic rate) has not been met, According to data presented in Alzheimer's Association Media Release.
- 30 Jul 2024 According to Alzheimer's Association Media Release, data from this trial presented at the Alzheimer's Association International Conference (AAIC) 2024, in Philadelphia and online.
- 13 Jun 2024 Status changed from active, no longer recruiting to completed.